lopinavir/ritonavir - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 1.12 [0.86, 1.46]> 124%3 studies (2 / 1)80.2 %criticalnot evaluable very lowcrucial-
clinical improvement (28-day) 1.59 [0.84, 3.03]> 10%1 study (1 / -)92.1 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 1.21 [0.96, 1.53]> 10%2 studies (1 / 1)94.5 %criticalnot evaluable very lowcrucial-
clinical worsening 3.69 [0.37, 36.57]< 10%1 study (1 / -)13.4 %some concernnot evaluable moderatecrucial-
deaths 1.00 [0.80, 1.25]< 114%2 studies (2 / -)49.7 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.04 [0.91, 1.18]< 10%1 study (1 / -)27.7 %some concernnot evaluable moderatecrucial-
PCR-negative conversion 0.84 [0.59, 1.19]> 10%2 studies (1 / 1)16.7 %criticalnot evaluable very lowimportant-
PCR-negative conversion (14-day) 0.92 [0.80, 1.06]> 10%2 studies (2 / -)12.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 0.73 [0.37, 1.43]> 12%2 studies (2 / -)18.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 0.83 [0.58, 1.18]> 10%1 study (- / 1)15.2 %criticalnot evaluable very lowimportant-
radiologic improvement (14-day) 0.75 [0.53, 1.06]> 10%2 studies (2 / -)4.9 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.10 [0.00, 2.09]> 10%1 study (1 / -)7.2 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 91, 95, 87